Key facts
- Novo Nordisk CEO Mike Doustdar believes the obesity drug market will not be winner-take-all.
- Doustdar anticipates market segmentation as new treatments emerge.
- He compares the obesity drug market to the diverse insulin offerings for diabetes.
- Hims & Hers plans to offer legally available peptides in 2026.
- Hims & Hers aims to sell peptides including NAD+, sermorelin, and glutathione.
- Wall Street analysts are cautious about the revenue impact of Hims & Hers' peptide launch.
- The peptides Hims & Hers plans to sell are already legally available.
- This existing availability limits revenue growth potential for Hims & Hers.
Novo Nordisk CEO Mike Doustdar stated that the rapidly expanding obesity drug market is unlikely to become a winner-take-all situation. He envisions a segmented market where various new treatments will cater to different needs, drawing a parallel to the wide array of insulin products available for diabetes management. This perspective suggests that multiple companies, including Novo Nordisk and its competitor Eli Lilly, can coexist and thrive.